Literature DB >> 31019778

Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis.

Hayoung Choi1, Hyun Lee2, Kyeongman Jeon3, Gee Young Suh3, Sumin Shin4, Hong Kwan Kim4, Kyunga Kim5,6, Daecheon Jeong5, Hojoong Kim3.   

Abstract

BACKGROUND: Surgical resection is the cornerstone treatment for pulmonary mucormycosis, a lethal fungal infection. It is unclear why some patients do not receive surgery, and the natural courses of these patients have not been well evaluated.
METHODS: A retrospective review was performed using the medical records of 20 patients with pathologically-confirmed pulmonary mucormycosis. We evaluated the reasons for not receiving surgery and compared treatment outcomes between patients who did and did not undergo surgery.
RESULTS: Overall survival rate was 50%. Nine of 11 (82%) patients who underwent surgery survived; however, only 1 of 9 (11%) patients who did not undergo surgery survived. Reasons for not receiving surgery were death shortly after diagnosis (n=1), altered mental state (n=1), refractory underlying disease (n=3), and refusal by patient due to concern of operative risk (n=4). Patients who did not undergo surgery were more likely to be older (P=0.018), have a longer duration of steroid use (P=0.021), higher lactate dehydrogenase level (P=0.039), higher sequential organ failure assessment (SOFA) score (P=0.035), and higher rate of cytomegalovirus (CMV) infection (P=0.020) than those did receive surgery. Surgery was the only favorable survival factor in multivariable analyses (adjusted odds ratio for survival =15.45; P=0.029).
CONCLUSIONS: The main reasons for not undergoing surgery in patients with pulmonary mucormycosis were the gravity of underlying diseases and concerns for operative risk. Although overall survival rate was poor, it was significantly higher in patients who received pulmonary resection surgery. The decision to undergo lung resection is time-sensitive and essential in improving survival rate in patients suffering from pulmonary mucormycosis, despite perioperative risks.

Entities:  

Keywords:  Invasive fungal infection; mucormycosis; survival; thoracic surgery

Year:  2019        PMID: 31019778      PMCID: PMC6462693          DOI: 10.21037/jtd.2019.01.75

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  23 in total

1.  Impact of zygomycosis on microbiology workload: a survey study in Spain.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Patricia Muñoz; Ignacio Gadea; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

2.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

3.  Reversed halo sign in invasive pulmonary fungal infections.

Authors:  Hisham Wahba; Mylene T Truong; Xiudong Lei; Dimitrios P Kontoyiannis; Edith M Marom
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

Review 4.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

5.  The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.

Authors:  Livio Pagano; Morena Caira; Anna Candoni; Massimo Offidani; Luana Fianchi; Bruno Martino; Domenico Pastore; Marco Picardi; Alessandro Bonini; Anna Chierichini; Rosa Fanci; Cecilia Caramatti; Rosangela Invernizzi; Daniele Mattei; Maria Enza Mitra; Lorella Melillo; Franco Aversa; Maria Teresa Van Lint; Paolo Falcucci; Caterina Giovanna Valentini; Corrado Girmenia; Annamaria Nosari
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

6.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

Review 7.  Pulmonary mucormycosis: the last 30 years.

Authors:  F Y Lee; S B Mossad; K A Adal
Journal:  Arch Intern Med       Date:  1999-06-28

Review 8.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 9.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

10.  Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997.

Authors:  Hikaru Kume; Toshikazu Yamazaki; Michiko Abe; Hiroyuki Tanuma; Masahiko Okudaira; Isao Okayasu
Journal:  Pathol Int       Date:  2003-11       Impact factor: 2.534

View more
  11 in total

1.  Pulmonary mucormycosis after renal transplantation: A case report and a literature review.

Authors:  Ekhlass Abu Asabeh; Zahraa M M Zeer; Osama N Dukmak; Mohammad Eid Al Mohtasib; Yousef Abu Asbeh
Journal:  Ann Med Surg (Lond)       Date:  2022-06-01

2.  Emerging Invasive Fungal Infections in Critically Ill Patients: Incidence, Outcomes and Prognosis Factors, a Case-Control Study.

Authors:  Romaric Larcher; Laura Platon; Matthieu Amalric; Vincent Brunot; Noemie Besnard; Racim Benomar; Delphine Daubin; Patrice Ceballos; Philippe Rispail; Laurence Lachaud; Nathalie Bourgeois; Kada Klouche
Journal:  J Fungi (Basel)       Date:  2021-04-24

3.  Characteristics of pulmonary mucormycosis and the experiences of surgical resection.

Authors:  Weipeng Shao; Jun Zhang; Shanwu Ma; Hongxiang Feng; Zhenrong Zhang; Chaoyang Liang; Deruo Liu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

4.  Characteristics of Mucormycosis in Hematological Patients and a Death Prediction Model.

Authors:  Xiaoxu Ma; Ang Li; Weijie Cao; Huiling Li; Suping Zhang; Li Li; Haizhou Xing; Wenliang Tian; Pengfei Jiao; Jiajun Chen; Qingxian Zhang; Aiguo Xu; Lihua Xing
Journal:  Front Microbiol       Date:  2021-12-15       Impact factor: 5.640

5.  Commentary: Pneumonectomy for resection of pulmonary mucormycosis: Enough is never too much.

Authors:  Robert E Merritt
Journal:  JTCVS Tech       Date:  2021-10-28

6.  Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.

Authors:  Reshma P Chavan; Shivraj M Ingole; Hamna Abdul Nazir; Wilson V Desai; Gajanan S Kanchewad
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-05       Impact factor: 3.236

7.  Pulmonary mucormycosis with extensive bronchial necrosis and bronchomediastinal fistula: A case report and review.

Authors:  S Seifert; J Wiley; J Kirkham; S Lena; K Schiers
Journal:  Respir Med Case Rep       Date:  2020-05-06

8.  Pulmonary mucormycosis: a case of pulmonary arterial hypertension, Westermark sign, and bronchopleural fistula.

Authors:  Weipeng Shao; Zhenrong Zhang; Hongxiang Feng; Chaoyang Liang; Deruo Liu
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

Review 9.  Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.

Authors:  Shreya Dogra; Akanksha Arora; Aashni Aggarwal; Gautam Passi; Akanksha Sharma; Gurpal Singh; Ravi P Barnwal
Journal:  Front Microbiol       Date:  2022-01-04       Impact factor: 5.640

10.  Outcomes of early anti-fungal therapy with aggressive surgical resection in pulmonary mucormycosis.

Authors:  Mohan Venkatesh Pulle; Harsh Vardhan Puri; Belal Bin Asaf; Sukhram Bishnoi; Shikha Sharma; Arvind Kumar
Journal:  Lung India       Date:  2021 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.